Bortezomib (PS-341)

製品コードS1013 別名:LDP-341, MLM341

Bortezomib (PS-341)化学構造

分子量(MW):384.24

Bortezomib (PS-341)は一種の有効な20Sプロテアソーム阻害剤で、Ki値が0.6nMですが、正常細胞より腫瘍細胞に良好な選択性をもっと表します。

サイズ 価格 在庫  
JPY 10079.16 あり
JPY 38876.76 あり
JPY 96471.96 あり

文献中の引用(143)

カスタマーフィードバック(21)

  • Indisulam dependent degradation of RBM39 can be blocked by bortezomib, a proteasome inhibitor. Cells were pretreated with indicated concentrations of bortezomib for 2 hours, followed by 6 hours of treatment with 2 μM indisulam. The effect of bortezomib is attenuated in a bortezomib resistant cell line.

    Science, 2017, eaal3755. Bortezomib (PS-341) purchased from Selleck.

    Effect of different proteasome inhibitors on dysferlin expression and on membrane resealing in cultured primary myoblasts. Primary myoblasts from patient 2 harboring a homozygous Arg555Trp DYSF mutation that were treated with the indicated amounts of bortezomib for 24 hours. Western blots of protein extracts were stained with anti-dysferlin antibodies and with anti–a-tubulin antibody as loading control.

    Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck.

  • Pharmacologic inhibition of the proteasome blocks proplatelet formation in murine and human megakaryocytes. Human megakaryocytes were pretreated with vehicle or bortezomib, and megakaryocytes producing proplatelets (PP) were examined. Shown are representative transmission images and representative confocal images with wheat germ agglutinin (WGA; red) and phalloidin (green) staining. Scale bars: 50 um.

    J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck.

    Immunofluorescence showing HDAC4 localization in mouse primary osteoblasts treated with vehicle or PTH alone or in the presence of bortezomib. Primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib for 2 h using anti-HDAC4 and anti-b-actin antibodies.

    J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck.

  • Effects of NF-kB inhibition on cell proliferation and apoptosis in Foxp3cKO prostate. A. Top left panels: Representative H&E staining of PIN lesions in ventral prostates of 60-week-old PBS- or bortezomib-treated Foxp3cKO littermates. Scale bar, 50 祄. Right graph: Quantification of Ki67-positive cells identified by IHC analysis (bottom left panels) as a measure of cell proliferation, performed with Scion Image software. Horizontal lines represent the average values. The p value was determined by two-tailed t test. B. Representative western blots showing p65 and nuclear p65 (N-p65) expression in prostates at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. C. Quantification of Bcl2l1 and Traf1/2 mRNA expression as a percentage of Hprt expression measured in microdissected mouse prostate epithelial cells by qPCR at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. Horizontal lines represent the average values. The p values were determined by two-tailed t test. D. Left panels: Representative images of TUNEL assays performed on prostates from PBS- or bortezomib-treated mice at 60 weeks of age. Insets show the apoptotic cells (green) in prostate glands. Scale bar, 100 祄. Right graph: Quantification of apoptotic cells in the ventral and dorsolateral prostates of PBS- or bortezomib-treated mice at 45 and 60 weeks of age. Horizontal lines represent the average values. The p value was determined by two-tailed t test. cKO, PB4-Cre4+Foxp3flox/y; wks, weeks; B/P, ratio of the mean value from bortezomib-treated mice to the mean value in PBS-treated mice. All experiments were repeated two times. Wks, weeks.

    Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck.

    Inhibition of proteasome and lysosome or silencing of VCP and co-factors lead to the accumulation of OP-puro-labeled DRIPs adjacent to or within SGs. HeLa cells were co-treated for 45 min with OP-puro and arsenite (Ars.); where indicated, cells were pretreated with bortezomib (Bort.) overnight and/or ammonium chloride (NH4Cl) for 2 h 15 min. Cells were fixed and labeled with Alexa594-Azide and anti-TIA-1.

    Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck.

  • Control wild-type and Fmn2–/–oocytes observed at different stages of meiotic maturation [prophase I (Pro I), NEBD, 3 hours and 8 hours after NEBD] using anti-Fmn2. wt + Bortezo, wild-type oocytes treated with 0.1μM Bortezomib for 90 minutes before fixation. All oocytes were observed using the same settings and the images treated the same way (three independent experiments). Red arrows indicate cortical labeling. Scale bar: 10μm.

    Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck.

    Immunofluorescence analysis for Ser536 p-NF-κB cellular localization of RS4;11cells treated with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. Cells were treated, collected at 22 h and reacted with an antibody to Ser536 p-NF-κB which was revealed by a Cy3-conjugated secondary antibody. DAPI was used to label nuclei.

    Oncotarget, 2015, 51: S659-S660. Bortezomib (PS-341) purchased from Selleck.

  • (B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

    LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

     

     

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

  • The stable cell line HepAD38 was incubated for 18 h in the presence of the indicated amount of Bortezomib. The medium was removed and replaced by medium containing Bortezomib dissolved in PBS. In case of the control cells the same amount of PBS was added to the medium. 4 h later this procedure was repeated and again 14 h later the supernatant was collected. The amount of viral particles was quantified by real time PCR. HBV-genome quantification was done using COBAS® AmpliPrep/COBAS® TaqMan® HBV test (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. The assay shows relative values (the value for untreated control cells was arbitrarily set as 1) that are based on three independent experiments. The cell viability was analyzed by MTT assays. For does up to 50 nM no significant effect on cell viability was observed within 18h, for 100 nM the proportion of metabolically active cells was reduced to 83%.

    J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck.

    PS-341 impairs FPV replication in A549 cells. (A and B)A549 cells were either pretreated for 1 h with different concentrations of PS-341 or with solvent only or were left untreated. Then, cells were infected with FPV at an MOI of 0.001 (A) or 0.05 (B). After virus inoculation cells were posttreated with different concentrations of PS-341. (A) At 24 h p.i. supernatants were obtained and progeny virus titers were measured by standard plaque assay. (B)Proteasome activity and the ability of PS-341 to inhibit the proteasome was determined 24 h p.i. (C) A549 cells were pretreated with 50 nM PS-341 or solvent or left untreated for 1 h. Afterwards cells were infected with FPV at an MOI of 0.0005. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or solvent or left untreated. After the indicated times p.i.supernatants were obtained and progeny virus titers were determined by standard plaque assay. Arrow bars in all experiments represent standard deviations of three independent experiments.

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • Early steps of viral replication within the first replication cycle are affected. (A) For time-of-addition kinetics analysis, A549 cells were either left untreated or were pretreated for 10 h or 1 h with 50 nM PS-341 before infection and additionally posttreated after infection. Cells were infected with FPV at an MOI of 0.005. After virus inoculation cells were posttreated with 50 nM PS-341. Then the proteasome inhibitor was added after virus inoculation (10 h, 1 h, and 30 min) or it was added at the different times p.i. as indicated (1 h, 2 h, 4 h, 6 h, and 8 h; cells were not pretreated before infection). At 9 h p.i. supernatants were obtained and progeny virus titers were determined by standard plaque assay. Shown is one representative experiment out of three independent experiments. (B) A549 cells were pretreated with 50 nM PS-341 or left untreated for 1 h. Afterwards cells were infected with avian FPV or human PR8 at an MOI of 1. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or left untreated. After the indicated times p.i. cells were lysed and analyzed by Western blotting for accumulation of viral proteins polymerase PB1 and matrix protein M1. Cellular protein ERK2 served as a control to demonstrate equal amounts of protein loading. Shown is one representative blot out of three independent experiments.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    A549 cells were treated with PS-341 at 50 nM for the indicated times or left untreated. Western blotting was performed with total cell lysates, using phospho-specific antibodies against JNK and the transcription factors c-Jun and ATF-2 or loading controls, respectively.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • Western blot of extracts of infected cells treated with different proteasome inhibitors at different concentrations, reacted with the indicated antibodies. p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Time window treatment with proteasome inhibitors. (A) Scheme of the experiment performed with MA104 cells exposed to virus (OSU; MOI, 3) for 1 h and analyzed at the starting point and endpoint of the indicated time window treatments with DMSO, MG132, or bortezomib. (B) Western blot of cellular lysates derived from cells infected for the indicated time periods and treated with the proteasome inhibitors or DMSO. NI, noninfected cells. Blots were reacted with the indicated antibodies; p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Fluorescence analysis of viroplasm formation on NSP5-EGFP cells infected with rotavirus (OSU; MOI, 3) and treated or not treated with MG132 (10 M) or bortezomib (10 M) at different times p.i., as indicated. Cells were analyzed at the starting points (1 h, 3 h, 5 h, 7 h) and endpoints (9 h) of the inhibitor’s window treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Quantification of the accumulation of viroplasms in infected NSP5 -EGFP/MA104 cells. At different times p.i., cells were treated for 4 h with DMSO or the indicated proteasome inhibitor and the number of viroplasms/cell was quantified at the starting (1 h, 3 h, 5 h; white bars) and endpoints (5 h, 7 h, 9 h) of treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Proteasome inhibition effect on biotinylation of MHC-Iα. (a) WB-ra of cellular extracts of HEK293 cells co-transfected with BAP-MHC-Ia and cyt-BirA (control) and, where indicated, with US2 or US11 in the absence (2) or presence of MG132 (MG; 50 μM for 4 h) or Bortezomib(Bort.; 50 μM for 4 h).

    PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck.

     

    KKU-M213 was treated with BTZ as indicated. Total cell lysate ( a) and nuclear extract (b) were prepared. Actin and γ -tubulin were loading controls for total and nuclear proteins, respectively.

    2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck.

  • Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck.

製品安全説明書

Proteasome阻害剤の選択性比較

生物活性

製品説明 Bortezomib (PS-341)は一種の有効な20Sプロテアソーム阻害剤で、Ki値が0.6nMですが、正常細胞より腫瘍細胞に良好な選択性をもっと表します。
ターゲット
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
体外試験

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 NWGw[GN2S3m2b4TvfIlkKEG|c3H5 NGS4TG42OCEQvF2= MWS0PEBp M3TmfGROW09? MWrLbYxteyClZXzsd{BjgSCvb4LlJJRp[W5iOUml M4LO[|ExPDl7NkSz
OVCA 429 MULGeY5kfGmxbjDBd5NigQ>? MmXJN|AxKG6P NVu0OG9yPDhiaB?= NWnCdXpQTE2VTx?= MX7EbZNzfXC2czDpcpRi[3RibYXseIlk\WyudXzhdkB1fW2xcjDzdIhmem:rZIO= NV;CeHB5OTB7OUm3OlY>
RPMI8226 M2G4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWKxNFAhdk1? NF3QZYY1QCCq M3\SUmROW09? NITST5BKSzVyPUOwJI5O NHWzVlMyOTNyNkS4PS=>
Dox40 NFvadpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLsNVAxKG6P Mk\2OFghcA>? Mk\ESG1UVw>? NGTMNHVKSzVyPUSwJI5O M4\BelEyOzB4NEi5
MR20 MonZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHpNVAxKG6P MlzWOFghcA>? MYHEUXNQ MWnJR|UxRTJyIH7N NGDwNoMyOTNyNkS4PS=>
LR5 NFrIcpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\XNVAxKG6P M2fGTVQ5KGh? NVnINHJvTE2VTx?= Mkf6TWM2OD1{MDDuUS=> NWHpTZZtOTF|ME[0PFk>
U266 NHTmWZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnJW5EyODBibl2= Ml7aOFghcA>? MnvpSG1UVw>? NIP5cplKSzVyPUOgcm0> Ml;sNVE{ODZ2OEm=
IM-9 NGmySHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWr0R3V7OTByIH7N NYPoZXVsPDhiaB?= NVzifWtRTE2VTx?= M17V[WlEPTB;NjDuUS=> MnTjNVE{ODZ2OEm=
Hs Sultan MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXru[XlDOTByIH7N MYe0PEBp NIPiflVFVVOR NXftXVc6UUN3ME2yNEBvVQ>? MoHYNVE{ODZ2OEm=
PAM-LY2 M1zybmZ2dmO2aX;uJGF{e2G7 M3jhN|ExOCCwTR?= NYPvVYdQOTJiaB?= MUjEUXNQ MVTJcohq[mm2czDOSk3PwkJiYXP0bZZifGmxbh?= MmLTNVE{PTB7MUO=
PAM 212 NEe3TpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIW1cHMyODBibl2= MXG3NkBp MmfPSG1UVw>? NGPxZ2dKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= NX\4TFJNOTF|NUC5NVM>
PAM-LY2 NY\tPVU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDmZ4hmOTByIH7N Mn7TO|IhcA>? MVjEUXNQ NXLIdnZwUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= NUHucYhTOTF|NUC5NVM>
B4B8 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;CflExOCCwTR?= M1fhS|czKGh? NYH1cnh4TE2VTx?= MWPJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? NIjEVZIyOTN3MEmxNy=>
B7E3 MoDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPhRpNwOTByIH7N MWW3NkBp NGPoUXJFVVOR MYnJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? MlzoNVE{PTB7MUO=
UM-SCC-9 NV;jbnJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIn4bWgyODBibl2= MkjLO|IhcA>? M1K4S2ROW09? MlLpTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? M4j2SlEyOzVyOUGz
UM-SCC-11B NGDw[nlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYexNFAhdk1? MX63NkBp NF7Ue3pFVVOR MWXJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? MX2xNVM2ODlzMx?=
H460 M2jtfmZ2dmO2aX;uJGF{e2G7 MkW1NVAh|ryP MmH3NlQhcA>? M{PuVGROW09? M2PWR2lv\HWlZYOgRoNtNTJicHjvd5Bpd3K7bHH0bY9vKGGwZDDjcIVifmGpZTDjc5Jz\WyjdHXkJJdqfGhiR{KtUUBxcGG|ZTDhdpJme3R? M3iyPFEzPDl{MUG3
U266 NUDDbFk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TFdlUxOCCwZz;tcC=> MnK5OFghcA>? NUC5SmtOTE2VTx?= M2D5c2lvcGmkaYTzJINmdGxiZ4Lve5Rp MWKxNlY{OTZzOR?=
ARH77 M3riVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vEbVUxOCCwZz;tcC=> Mo[2OFghcA>? M1H6T2ROW09? M1\h[WlvcGmkaYTzJINmdGxiZ4Lve5Rp MmfONVI3OzF4MUm=
WAD-1 NYH6XZdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHOdYg2ODBibnevcYw> M1rhWlQ5KGh? NFf3b|RFVVOR M4LMXGlvcGmkaYTzJINmdGxiZ4Lve5Rp NF61Z2kyOjZ|MU[xPS=>
U266/LR7 NFjtNXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPrc4NYPTByIH7nM41t NUmyU4V{PDhiaB?= NU\VUlZ2TE2VTx?= MXLJcohq[mm2czDj[YxtKGe{b4f0bC=> MknJNVI3OzF4MUm=
U266/dox4 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHX[os2ODBibnevcYw> NVG2fWRLPDhiaB?= MWLEUXNQ M1PBVGlvcGmkaYTzJINmdGxiZ4Lve5Rp MX2xNlY{OTZzOR?=
RPMI8226/LR5 M4e0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV:1NFAhdmdxbXy= NH63VY81QCCq MmLsSG1UVw>? NYnOPVdjUW6qaXLpeJMh[2WubDDndo94fGh? Mm\DNVI3OzF4MUm=
H460 MoDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXFTW8yOCEQvF2= M2LJNFczKGh? MXfEUXNQ NWjGTHdSUUN3ME2xNFAhdk1? M{PFbVEzPjNzNkKw
H358 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWSxNEDPxE1? NIG5[pk4OiCq NWG0cm9oTE2VTx?= M2jX[GlEPTB;N{Cgcm0> M4f6elEzPjNzNkKw
H322 NGXUOplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPIXZMyOCEQvF2= MWq3NkBp NWHWNnA4TE2VTx?= MV\JR|UxRTZ{MDDuUS=> NGHmWG4yOjZ|MU[yNC=>
H460 NXv2Z3d5TnWwY4Tpc44hSXO|YYm= Ml33NVAxKG6P MlnVNlQhcA>? NXmxNWxFTE2VTx?= Mn\CTY5lfWOnczDHNk1ONXCqYYPlJIFzemW|dDDhcoQhfHWkdXzpckBie3OnbXLsfU1lcXOjc4PlcYJtgQ>? NHfuZosyOjZ|MU[yNC=>
LNCap-Pro5 NHLHTZlHfW6ldHnvckBCe3OjeR?= MYSxJO69VQ>? MXi0JIg> M{XXWGROW09? MUfTeIFjcWyrenXzJJA2Ow>? M3LkZ|E1PjF{NUOy
T29 M3nj[2Fxd3C2b4Ppd{BCe3OjeR?= NW\LOmVLPTBibl2= NVX3XFI3PDhiaDC= NXToVJN{TE2VTx?= M1zDVmlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MVqxOlc4QDF5OR?=
T29Kt1 MUXBdI9xfG:|aYOgRZN{[Xl? NUnjNWZKPTBibl2= NVWzV|I4PDhiaDC= MYjEUXNQ MXvJcoR2[2W|IHPlcIwh[XCxcITvd4l{ NXrL[|ZmOTZ5N{ixO|k>
HCT116 M2XsR2Fxd3C2b4Ppd{BCe3OjeR?= NX;lbZdyPTBibl2= M4HIb|Q5KGhi Mk\rSG1UVw>? MVHJcoR2[2W|IHPlcIwh[XCxcITvd4l{ MXqxOlc4QDF5OR?=
HKe-3 NX;vNWxMSXCxcITvd4l{KEG|c3H5 MmS1OVAhdk1? NHrx[ZU1QCCqIB?= MXLEUXNQ M3vxVWlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MlrMNVY4PzhzN{m=
NB-1691 NFT0UFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY[xJO69VQ>? NGLtSng4OiCq MX;Jcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hPSV? MX[xO|Y5QTZ6NB?=
CHLA-255 M3vKfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUW1NIhEOSEQvF2= MXi3NkBp NX3XRlY6UW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKHSxIEKl M3jaeVE4Pjh7Nki0
SK-N-AS M2LEeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\rU3AyKM7:TR?= NFe0WJk4OiCq MYnJcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hOTBn NVvmbW9IOTd4OEm2PFQ>
NB-1691 M3fzdmZ2dmO2aX;uJGF{e2G7 NYrlOHZyOTBibl2= MVeyOEBp MWXTbYdvcW[rY3HueIx6KHKnZIXj[ZMh[2WubIOgbY4hfGinIFewM2cyKHCqYYPl Mom5NVc3QDl4OES=
CHLA-255 MXnGeY5kfGmxbjDBd5NigQ>? NYjhNWViOTBibl2= Ml7vNlQhcA>? MWDNc4Rme3SueTDy[YR2[2W|IHPlcIx{KGmwIITo[UBIOC:JMTDwbIF{\Q>? NFrVfZEyPzZ6OU[4OC=>
RPMI 8226 MkL1SpVv[3Srb36gRZN{[Xl? M4HQflIxKG6P MUG4JIg> MXfTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> M4TEdlE6PDN4MEWw
MM.1S M3vBdWZ2dmO2aX;uJGF{e2G7 NXXUV3NkOjBibl2= MkLCPEBp NEHZbmdUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? MkXGNVk1OzZyNUC=
U266 MVrGeY5kfGmxbjDBd5NigQ>? MliwNlAhdk1? MkjuPEBp NFG5fIdUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? NXLObHg2OTl2M{[wOVA>
OPM1 NFLFRYRHfW6ldHnvckBCe3OjeR?= NGnKXlAzOCCwTR?= NUCzdmNTQCCq M1;nOnNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 Ml3tNVk1OzZyNUC=
INA6 MlzQSpVv[3Srb36gRZN{[Xl? M3KwVlIxKG6P MnrWPEBp NYrUfI17W2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? MmX2NVk1OzZyNUC=
OPM2 NVvHN4tOTnWwY4Tpc44hSXO|YYm= MUeyNEBvVQ>? NHnndJQ5KGh? NFn5W4lUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? MmT6NVk1OzZyNUC=
RPMI 8226 NXnPWFlXTnWwY4Tpc44hSXO|YYm= NWTtR5FtOjBibl2= M3;tVFghcA>? MnzBTY5lfWOnczDEUmEhe3mwdHjld4l{ NWHZcoxxOTl2M{[wOVA>
BaF/3 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHtNVAxKG6P Mlr5OFghcA>? MkDlTWM2OD14LkKgcm0> Mn2xNlA{ODV4OUK=
BaF/3-p210 M2XYd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfseYEyODBibl2= MYm0PEBp M{HiOGlEPTB;ND63JI5O NEi4WG4zODNyNU[5Ni=>
TCC-S M{HWbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\mdXVIOTByIH7N NGjRS5A1QCCq NYnud4FIUUN3ME2yMlghdk1? NFTBc|EzODNyNU[5Ni=>
BaF/3 NIHubWpHfW6ldHnvckBCe3OjeR?= NV;ofYhyPiCwTR?= NXzBOG53PDhiaB?= MXTJcoR2[2W|IHGg[5Jm[XRiR{GgZ4VtdC2leXPs[UBienKnc4S= MkXvNlA{ODV4OUK=
BaF/3-p210 MnjNSpVv[3Srb36gRZN{[Xl? M1PzclYhdk1? MWq0PEBp M1TTU2lv\HWlZYOgZUB{dGmpaISgS|Eh[2WubD3jfYNt\SCjcoLld5Q> NWXCd2w6OjB|MEW2PVI>
BaF/3-p210 M3;2XGZ2dmO2aX;uJGF{e2G7 NVTXfpJGPiCwTR?= MWiyOEBp Ml\HVoVlfWOnczD0bIUheGixc4Doc5J6dGG2aX;uJIFv\CC2aHWgZYN1cX[rdImgc4YhWmJ? NF\vRmEzODNyNU[5Ni=>
Raji NWS0WHF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfJTodMOSEQvF2= M2jkclI1KGh? M3rHWnJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= NYfVfWE5OjFzN{C5PFg>
LCL-1 MlvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHFT3UyKM7:TR?= MWiyOEBp MXXS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? NUTKbms{OjFzN{C5PFg>
LCL-2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX2xJO69VQ>? NHzYSmIzPCCq MVrS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? NEKwVHgzOTF5MEm4PC=>
BJAB M{j4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17QOFEh|ryP MXSyOEBp M3HBN3Jm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= NFHsS24zOTF5MEm4PC=>
SNT-13 M4\GV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnFV5ZUOSEQvF2= NVfEdnhqOjRiaB?= M2fDVXJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= NVf1SVcyOjFzN{C5PFg>
SNT-16 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYKwd5Z5OSEQvF2= M3vFTFI1KGh? M1izVXJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= NFLQboUzOTF5MEm4PC=>
Jurkat M3jDfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEP3fGUyKM7:TR?= NVXnZpRbOjRiaB?= NESweXVT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NF;U[GczOTF5MEm4PC=>
KAI-3 NXL0TmpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrM[mE3OSEQvF2= NEPnc48zPCCq NI\YNY1T\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= M1fjWVIyOTdyOUi4
SNK-6 NF3se21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fHXlEh|ryP NXy4fHJoOjRiaB?= MU\S[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? MnnnNlEyPzB7OEi=
KHYG-1 NGfHVGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\jNUDPxE1? M1fnVVI1KGh? NXiyUIFMWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg M1jsSVIyOTdyOUi4
SNT-16 M1zJU2Fxd3C2b4Ppd{BCe3OjeR?= MUexJO69VQ>? M1TEPFYhcA>? NIK4WGNKdmS3Y3XzJINmdGxiYYDvdJRwe2m| NXy4eYJlOjFzN{C5PFg>
Jurkat MmHwRZBweHSxc3nzJGF{e2G7 MmLjNUDPxE1? MUK2JIg> NX3QdVVyUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NWjY[XdROjFzN{C5PFg>
KAI-3 MoHiRZBweHSxc3nzJGF{e2G7 NX\NcXliOSEQvF2= MkK0OkBp MUjJcoR2[2W|IHPlcIwh[XCxcITvd4l{ MXKyNVE4ODl6OB?=
KHYG-1 MmfZRZBweHSxc3nzJGF{e2G7 MVWxJO69VQ>? M4PKcVYhcA>? M4\QbWlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NI\vcFYzOTF5MEm4PC=>
SNT-13 NHz6NYVCdnSrdnnyZYwhSXO|YYm= NXHXW2IzOSEQvF2= NHPSeVkzPCCq NXHrRm1pUW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKY NX\ScHh7OjFzN{C5PFg>
SNT-16 MX3BcpRqfmm{YXygRZN{[Xl? M2n1dFEh|ryP Mlf2NlQhcA>? MkPwTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX NYO0TGRNOjFzN{C5PFg>
KAI-3 NGO3[G5CdnSrdnnyZYwhSXO|YYm= MXixJO69VQ>? Ml3hNlQhcA>? MUPJcoR2[2W|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY> MXOyNVE4ODl6OB?=
SNK-6 M37kZWFvfGm4aYLhcEBCe3OjeR?= MlXaNUDPxE1? MmXDNlQhcA>? M1fCcmlv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>? NHz0cokzOTF5MEm4PC=>
RAW 264.7 MmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGT5bWYyODBibl2= MWq0PEBp MX\S[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? NIraUnUzOjR{N{G1OC=>
A375 MkPnRZBweHSxc3nzJGF{e2G7 MVmxNEBvVQ>? NEizSJEzPCCq NYnXUWFiUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M{H4NFI{ODd7MEiz
BLM MWXBdI9xfG:|aYOgRZN{[Xl? MVKxNEBvVQ>? MVyyOEBp NIr3O2hKdmS3Y3XzJINmdGxiYYDvdJRwe2m| M4DqXlI{ODd7MEiz
A375 MVPBeZRweGijZ4mgRZN{[Xl? MlzzNVAhdk1? NHqxbpkyOiCq NF;ESnhKdmS3Y3XzJIZwem2jdHnvckBw\iCjdYTvdIhi\2:|b33ldy=> MVeyN|A4QTB6Mx?=
BLM MVXBeZRweGijZ4mgRZN{[Xl? M{jo[|ExKG6P MXSxNkBp M17Bfmlv\HWlZYOg[o9zdWG2aX;uJI9nKGG3dH;wbIFod3OxbXXz NWLhPHJ{OjNyN{mwPFM>
H1299 MlfMRZBweHSxc3nzJGF{e2G7 NWfCSYJxQDBibl2= MUiyOEBp NHnMRWpFVVOR NXrad|FMW2Wwc3n0bZpmeyCQU1PMR{Bk\WyuczD0c{BOW0NvZHXybZZm\CCrQ{mtbY5lfWOnZDDhdI9xfG:|aYO= NUPtbVdVOjV|MkO2PVM>
Hut-78 NUfhdWNTTnWwY4Tpc44hSXO|YYm= M3jGZVExOCCwTR?= NY\4V3g{OjRiaB?= M1rYOGROW09? NH7uVoVFd3ewcnXneYxifGW|IGTHSk3PujFiYX7kJGlNNTFyIHX4dJJme3Orb36= M{jhPFI2PjhzM{O1
H9 M1zvdWZ2dmO2aX;uJGF{e2G7 MXyxNFAhdk1? NX:xTmp[OjRiaB?= M2HvdmROW09? NIm4SHZFd3ewcnXneYxifGW|IGTHSk3PujFiYX7kJGlNNTFzIHX4dJJme3Orb36= M4HHXlI2PjhzM{O1
HH NH;ab3hHfW6ldHnvckBCe3OjeR?= NXr2Z5QyOTByIH7N NILScoIzPCCq NWLpc4lzTE2VTx?= Mni5[I94dnKnZ4XsZZRmeyCWR1[t{tIyKGGwZDDJUE0yOiCneIDy[ZN{cW:w NI\6SZQzPTZ6MUOzOS=>
Hut-78 Ml3FUYloemG2aX;uJGF{e2G7 M2q2T|ExOCCwTR?= MUGyOEBp M4XRTWROW09? NEHTfoFT\WS3Y3XzJINmdGxibXnndoF1cW:wIHL5JFgx6oDVOUCl NIjwRpAzPTZ6MUOzOS=>
HH NYPrSY5yVWmpcnH0bY9vKEG|c3H5 MWmxNFAhdk1? M1;rNVI1KGh? MmL6SG1UVw>? NVnySWxbWmWmdXPld{Bk\WyuIH3p[5JifGmxbjDifUA5OOLCk{mxKS=> MYmyOVY5OTN|NR?=
U937 NYXFWWcxTnWwY4Tpc44hSXO|YYm= MlKzNVAxKG6P MofYOkBp M1zVWmlv\HWlZYOgTWwuQCCneIDy[ZN{cW:wIHnuJGxRWy2|dHnteYxifGWmIGW5N|chdWGlcn;wbIFo\XN? Mm\RNlU4QTF2N{e=
human PBMC MXHGeY5kfGmxbjDBd5NigQ>? MkLQNVAxKG6P NUnGdmF2OjRiaB?= NVznSlhwUW6mdXPld{BKVC16IILlcIVie2V? M37wSVI2PzlzNEe3
ES6 NH\CfFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPZfGJIUUN3ME2wMlAxOjFibl2= MkH4V2FPT0WU
SK-UT-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfDcXlKSzVyPUCuNVY{KG6P Mm\MV2FPT0WU
SH-4 NF7iXGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLzSnpwUUN3ME2wMlE4OyCwTR?= MYXTRW5ITVJ?
TE-9 MoTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrDTWM2OD1yLkG4NkBvVQ>? NV3kN4hFW0GQR1XS
A253 MmLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M36xOWlEPTB;MD6yNFghdk1? M135c3NCVkeHUh?=
no-10 NI\wTZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HuPGlEPTB;MD6yNUBvVQ>? M4f6W3NCVkeHUh?=
MMAC-SF MlG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\hTWM2OD1yLkKxOkBvVQ>? NXGxbIVSW0GQR1XS
A101D MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTBwMkK1JI5O NG[zTJhUSU6JRWK=
NTERA-S-cl-D1 M3LIdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTYTWM2OD1yLkK0N{BvVQ>? NX3HdGVKW0GQR1XS
8-MG-BA NHnHfItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PHcmlEPTB;MD6yOUBvVQ>? NYHpTXdNW0GQR1XS
KNS-42 M{DvU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Lpe2lEPTB;MD6yOVghdk1? NHjzclNUSU6JRWK=
LXF-289 NYCyW3BxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjwTWM2OD1yLkK2PUBvVQ>? NYn2[WkxW0GQR1XS
OVCAR-4 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3pTWM2OD1yLkK4PUBvVQ>? MnnOV2FPT0WU
LOUCY MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTBwMkmzJI5O MnjrV2FPT0WU
BB65-RCC M2W0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTLTWM2OD1yLkOwOEBvVQ>? NWXaRWdFW0GQR1XS
D-542MG M3PrVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXrbI5NUUN3ME2wMlMzQSCwTR?= NHH1d5VUSU6JRWK=
ONS-76 MnL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\4b4tzUUN3ME2wMlM{KG6P MofRV2FPT0WU
BB30-HNC NUDqNFBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1uxdWlEPTB;MD6zN|Uhdk1? MV;TRW5ITVJ?
KS-1 NVzCboVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13KU2lEPTB;MD6zOEBvVQ>? NIHVflRUSU6JRWK=
A388 MormS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwM{W2JI5O NX3GeZV2W0GQR1XS
ES8 M2TYO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwNDDuUS=> M1\mNnNCVkeHUh?=
MZ2-MEL M3HUXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzlVm1qUUN3ME2wMlQxPyCwTR?= M{\Z[nNCVkeHUh?=
HCC2998 NE\oPZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGj6Z5VKSzVyPUCuOFEzKG6P NYG2c45GW0GQR1XS
D-247MG MmrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHkclRZUUN3ME2wMlQyOyCwTR?= Ml;pV2FPT0WU
ACN MmHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlL0TWM2OD1yLkSxO{BvVQ>? M2TXVHNCVkeHUh?=
LB2518-MEL M3vRN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVj2O5hYUUN3ME2wMlQzPSCwTR?= MoD2V2FPT0WU
ES1 M3Lkcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTBwNEOgcm0> NVrIZ|VmW0GQR1XS
HCE-T NWL5bXlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTBwNEO5JI5O MoDIV2FPT0WU
OS-RC-2 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwNESgcm0> M2nmPXNCVkeHUh?=
MFH-ino MlX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LGSWlEPTB;MD60OFMhdk1? NITiWVZUSU6JRWK=
OCUB-M MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HNUGlEPTB;MD60OFchdk1? NWnWOIpjW0GQR1XS
CP66-MEL NU[5SoZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjrb|NKSzVyPUCuOFc{KG6P M1\Ic3NCVkeHUh?=
LB771-HNC NGfndGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUL6NJViUUN3ME2wMlQ4PCCwTR?= MkDKV2FPT0WU
DSH1 NEX1[XpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrKZ4I6UUN3ME2wMlQ5KG6P M3u2PXNCVkeHUh?=
HUTU-80 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnlbXpKSzVyPUCuOVM{KG6P NHTYWJlUSU6JRWK=
CESS NYHENo85T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHnNodKSzVyPUCuOVM5KG6P NYntOWoyW0GQR1XS
NCI-H747 Mon4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXDPVNJUUN3ME2wMlU{QSCwTR?= MXXTRW5ITVJ?
HT-144 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vCdmlEPTB;MD61O|Yhdk1? MlTwV2FPT0WU
COLO-829 M4nt[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmr6TWM2OD1yLk[xOEBvVQ>? NWTCbWJVW0GQR1XS
A4-Fuk M2XB[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPiVo9KSzVyPUCuOlI{KG6P NVPh[plvW0GQR1XS
GI-ME-N Mn3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;3OGlEPTB;MD62N|Qhdk1? MnvTV2FPT0WU
LB831-BLC MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fYe2lEPTB;MD62OFEhdk1? M1vsNnNCVkeHUh?=
HOP-62 NGLKcJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwNkS3JI5O Mnz4V2FPT0WU
BB49-HNC NYLhV2tYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwNkWyJI5O MorsV2FPT0WU
D-336MG Mm[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTBwNkW3JI5O Ml;xV2FPT0WU
TK10 M1X5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGj1eIVKSzVyPUCuOlc6KG6P MWrTRW5ITVJ?
Ramos-2G6-4C10 NXLZVlVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\vdng6UUN3ME2wMlY6OyCwTR?= NF7NfnRUSU6JRWK=
LB373-MEL-D M{S2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\TTWM2OD1yLkegcm0> MnvCV2FPT0WU
SF126 M1m2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkSzTWM2OD1yLkewNUBvVQ>? MWXTRW5ITVJ?
UACC-257 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTBwN{Ggcm0> MlTqV2FPT0WU
KINGS-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TMdGlEPTB;MD63NlIhdk1? Mnq1V2FPT0WU
LS-513 MoPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zX[GlEPTB;MD63N|khdk1? NHjPWHlUSU6JRWK=
GI-1 Mn;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWq2PYhJUUN3ME2wMlc3PCCwTR?= MkHXV2FPT0WU
ES7 M1ezcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWq3[mZvUUN3ME2wMlc3PiCwTR?= MmrQV2FPT0WU
LB2241-RCC MnHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3qzVmlEPTB;MD64NFQhdk1? NFPkbFlUSU6JRWK=
D-263MG NITFXlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUC5WFdLUUN3ME2wMlgxPyCwTR?= M{GzSnNCVkeHUh?=
SW684 NHT3TmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPOTWM2OD1yLkiyNUBvVQ>? Mk\tV2FPT0WU
ML-2 NEXId|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTBwOEKxJI5O MVTTRW5ITVJ?
SK-LMS-1 M4D5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTBwOEW0JI5O Ml7wV2FPT0WU
TE-5 M3H0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTBwOE[1JI5O NUj0VIQ1W0GQR1XS
QIMR-WIL NInnRXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfjOIpKSzVyPUCuPFg6KG6P M1rPOnNCVkeHUh?=
NCI-H1355 M4fZemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7jTWM2OD1yLki5OUBvVQ>? MYfTRW5ITVJ?
SNB75 NIfIeZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPJTWM2OD1yLkmxNkBvVQ>? MVXTRW5ITVJ?
RXF393 NFjGdGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jQ[WlEPTB;MD65NVQhdk1? MUfTRW5ITVJ?
IST-MEL1 NXWzWo9tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17FV2lEPTB;MD65NVchdk1? NG\Me2NUSU6JRWK=
SF268 M3ftNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljmTWM2OD1yLkmyN{BvVQ>? NFL5d4dUSU6JRWK=
KALS-1 Ml;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwOUK1JI5O M3nRcnNCVkeHUh?=
HC-1 M4[4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rmO2lEPTB;MD65O|Uhdk1? MWnTRW5ITVJ?
SW872 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTpbmFKSzVyPUCuPVk3KG6P NVLtUoVyW0GQR1XS
PSN1 MknsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DrZWlEPTB;MT6wNUBvVQ>? MmSzV2FPT0WU
TE-1 NHnsSYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPEfI9KSzVyPUGuNFMhdk1? MYjTRW5ITVJ?
TE-10 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LwcWlEPTB;MT6wN{BvVQ>? NWnNPFd[W0GQR1XS
RKO NWjlblV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjRWIxKSzVyPUGuNFYhdk1? Mo\FV2FPT0WU
LC-2-ad MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLrTWM2OD1zLkC4JI5O MWDTRW5ITVJ?
SK-MM-2 MlOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1f0TmlEPTB;MT6wPUBvVQ>? NETSdYpUSU6JRWK=
VA-ES-BJ NWD0TZZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYf5fIRrUUN3ME2xMlA6KG6P MVPTRW5ITVJ?
MZ7-mel NU[yUJM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTFwMEmgcm0> NVnKdVltW0GQR1XS
D-392MG MoPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;J[HRKSzVyPUGuNUBvVQ>? MnPoV2FPT0WU
CCRF-CEM M1XudGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TLNmlEPTB;MT6xN{BvVQ>? M2HFZnNCVkeHUh?=
EM-2 NEnXbVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vEW2lEPTB;MT6xOkBvVQ>? MV;TRW5ITVJ?
HAL-01 MnLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4D5VmlEPTB;MT6xPEBvVQ>? NFnzUI5USU6JRWK=
TE-8 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWK4fVN5UUN3ME2xMlE6KG6P NUTERlZoW0GQR1XS
NCI-H1882 M1ewZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7ScW1KSzVyPUGuNkBvVQ>? NGXYXGxUSU6JRWK=
Daudi NWjmRndNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\UUGlEPTB;MT6yNkBvVQ>? M1PhRnNCVkeHUh?=
BL-41 NX3Sbms1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnGXFFKSzVyPUGuNlUhdk1? MnnBV2FPT0WU
SR NGnMfYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXkVXNKSzVyPUGuNlUhdk1? MoLtV2FPT0WU
KM12 NV2zbHVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTFwMkegcm0> NWjQ[GNJW0GQR1XS
K5 NXHpTYhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XrUGlEPTB;MT6yPEBvVQ>? M1\0UXNCVkeHUh?=
A3-KAW NG\jNVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{m1VGlEPTB;MT6yPEBvVQ>? MkDFV2FPT0WU
CMK MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3[0TmlEPTB;MT6yPUBvVQ>? NXznZWxDW0GQR1XS
Calu-6 NGL6VGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXO3d5B5UUN3ME2xMlI6KG6P M3mzNHNCVkeHUh?=
IST-SL2 M{DOVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDMfXBSUUN3ME2xMlMyKG6P MYPTRW5ITVJ?
OPM-2 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnziTWM2OD1zLkOzJI5O NWfRWWlmW0GQR1XS
DU-4475 MlXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPh[ohwUUN3ME2xMlM3KG6P M2nsWHNCVkeHUh?=
ECC12 M1q2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDyNpZ7UUN3ME2xMlM4KG6P NXrCV|dRW0GQR1XS
L-540 M4fUfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTFwM{egcm0> NFTrXo9USU6JRWK=
CAS-1 NFXPSHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTFwM{egcm0> MnvXV2FPT0WU
PF-382 NFvZbWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\H[GlEPTB;MT60O{BvVQ>? M4nLdHNCVkeHUh?=
LS-411N MoSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTFwNUOgcm0> NGLRdVFUSU6JRWK=
NCI-H69 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonNTWM2OD1zLkW0JI5O NYizbWd1W0GQR1XS
NB12 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvFTWM2OD1zLkW2JI5O M2C1[nNCVkeHUh?=
HEL NGjndoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIn0co9KSzVyPUGuOlEhdk1? NVjueW1LW0GQR1XS
GCIY M2PuN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUG0TotJUUN3ME2xMlYzKG6P NHXuWoFUSU6JRWK=
EHEB MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTFwNkegcm0> NFXXe3JUSU6JRWK=
TGBC1TKB MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTFwN{Ggcm0> NFq4d|dUSU6JRWK=
KURAMOCHI MoK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rkN2lEPTB;MT63NkBvVQ>? MYXTRW5ITVJ?
U-266 NWrUfoFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\IdGlEPTB;MT63OkBvVQ>? NVjIfYp7W0GQR1XS
LC4-1 NYrpdHd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\YNWhHUUN3ME2xMlc6KG6P NUjBTWt[W0GQR1XS
NCI-H2126 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLLTWM2OD1zLkigcm0> NUHrXYpxW0GQR1XS
NCI-H1092 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7tTWM2OD1zLkigcm0> NX76SWhSW0GQR1XS
GB-1 NUfFd3BVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\HZ5ZKSzVyPUGuPFEhdk1? MVzTRW5ITVJ?
MV-4-11 NILoVWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTtTWM2OD1zLkiyJI5O NF;wdHpUSU6JRWK=
Becker NEftd2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;QeolKSzVyPUGuPFMhdk1? MlXmV2FPT0WU
MPP-89 MlnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;PcmlEPTB;MT64PUBvVQ>? MnHGV2FPT0WU
BE-13 NGDpfZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTFwOUOgcm0> MonRV2FPT0WU
697 NIHz[2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;jTWM2OD1zLkm5JI5O Mk\5V2FPT0WU
NKM-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLNTWM2OD1{IH7N NIXDOJVUSU6JRWK=
NB13 Ml35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTJibl2= M4jSfnNCVkeHUh?=
LS-123 NWqzUJV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfGTWM2OD1{LkCyJI5O MWnTRW5ITVJ?
NB17 M4\FT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLub2FqUUN3ME2yMlA1KG6P MX7TRW5ITVJ?
LAN-6 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1q1W2lEPTB;Mj6wOUBvVQ>? MkHwV2FPT0WU
EW-24 M1frdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjhTWM2OD1{LkC4JI5O M1TYRXNCVkeHUh?=
NOS-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTJwMUGgcm0> NVS4PWM4W0GQR1XS
BL-70 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFj0bGlKSzVyPUKuNVIhdk1? NGXUSHFUSU6JRWK=
GT3TKB NXO4bmhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Xh[mlEPTB;Mj6xNkBvVQ>? NUXaV|YzW0GQR1XS
HH MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPRTWM2OD1{LkGzJI5O NGHWT45USU6JRWK=
KE-37 NIrRSlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmH5TWM2OD1{LkGzJI5O M3n6XXNCVkeHUh?=
MOLT-4 NITBSWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13jUGlEPTB;Mj6xN{BvVQ>? NGfhVoFUSU6JRWK=
EKVX NULqU|VzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;5TWM2OD1{LkG0JI5O NFLvWoVUSU6JRWK=
KGN MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fwR2lEPTB;Mj6xOUBvVQ>? MYXTRW5ITVJ?
ES4 MnHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTJwMU[gcm0> MUjTRW5ITVJ?
SJSA-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYK4Z|lnUUN3ME2yMlIyKG6P M165VHNCVkeHUh?=
KMOE-2 M1yzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzPWlJKSzVyPUKuNlMhdk1? NXrybVNoW0GQR1XS
NB5 NYr3cVFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;MemlEPTB;Mj6yO{BvVQ>? MU\TRW5ITVJ?
BC-1 NWLJUXFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTJwM{Ggcm0> NFjUfYlUSU6JRWK=
NB10 NY\WSJp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7ZTWM2OD1{LkOyJI5O NYDuV3FKW0GQR1XS
RPMI-8226 NWe5NIcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTJwM{Wgcm0> Mm\lV2FPT0WU
SCC-3 NHTHepJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3UTWM2OD1{LkO3JI5O NEPnSnZUSU6JRWK=
ARH-77 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYr4UGw4UUN3ME2yMlM5KG6P MYjTRW5ITVJ?
NCI-H748 M161NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTJwM{mgcm0> NGn4c45USU6JRWK=
KU812 MkTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIL3dI9KSzVyPUKuOFIhdk1? NEXqdW9USU6JRWK=
NCI-H64 NILoUZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTJwNESgcm0> M3rrdHNCVkeHUh?=
NB69 M4PNUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXm1RoptUUN3ME2yMlQ3KG6P M1G0W3NCVkeHUh?=
KNS-81-FD NVrLW2R{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlP4TWM2OD1{LkS4JI5O MnruV2FPT0WU
LB1047-RCC NVy0R3h[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;iTWM2OD1{LkW3JI5O Mnz4V2FPT0WU
EB-3 NX;obINWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDTTWM2OD1{Lk[2JI5O MVTTRW5ITVJ?
Mo-T NYf5Z3YyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTJwN{Sgcm0> M2[xVnNCVkeHUh?=
EW-16 NXPIbJJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofPTWM2OD1{Lke1JI5O M33afHNCVkeHUh?=
CTV-1 MlvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;OTWM2OD1{Lkigcm0> NUGz[mN{W0GQR1XS
ETK-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUH6RYlGUUN3ME2yMlg1KG6P NV;VZ4l6W0GQR1XS
C2BBe1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XkRmlEPTB;Mj64PUBvVQ>? M1SxcXNCVkeHUh?=
MOLT-16 MlvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTJwOEmgcm0> M{\6U3NCVkeHUh?=
SW954 MmTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHey[nVKSzVyPUKuPUBvVQ>? MofNV2FPT0WU
HT M3fjb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPmPFBEUUN3ME2zMlAzKG6P M3\u[XNCVkeHUh?=
KARPAS-299 M1fWTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\JTWM2OD1|LkC2JI5O NELZbG1USU6JRWK=
MONO-MAC-6 NF\GO45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofGTWM2OD1|LkGgcm0> M3exdXNCVkeHUh?=
CGTH-W-1 NGjZTFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfTTYhKSzVyPUOuNUBvVQ>? NYXucVRMW0GQR1XS
SK-PN-DW Ml3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTNwMUSgcm0> NILKXoVUSU6JRWK=
CW-2 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrOW4xFUUN3ME2zMlIyKG6P MlnCV2FPT0WU
SK-N-DZ NWLlc2prT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHRN2w3UUN3ME2zMlI3KG6P NXv2dJF3W0GQR1XS
NEC8 NEDkb|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH32VIpKSzVyPUOuN|Uhdk1? NEfTZWlUSU6JRWK=
LB996-RCC MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTXb4pQUUN3ME2zMlQhdk1? M{LES3NCVkeHUh?=
DB NYPkS|ZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTNwNEGgcm0> M2DRWXNCVkeHUh?=
TE-15 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTNwNEOgcm0> M4\ZWHNCVkeHUh?=
COR-L88 MkG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrKWWlEUUN3ME2zMlQ4KG6P M2jJPHNCVkeHUh?=
LAMA-84 NImzflFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLmU|FKSzVyPUOuOFkhdk1? NGrtbFlUSU6JRWK=
MEG-01 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jncWlEPTB;Mz60PUBvVQ>? NVTQXYdQW0GQR1XS
LOXIMVI MlHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXSSYJKSzVyPUOuOUBvVQ>? M{ewWHNCVkeHUh?=
RPMI-8402 Ml\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jY[2lEPTB;Mz61JI5O MmTVV2FPT0WU
KARPAS-45 NYHKbmR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\GNWlKSzVyPUOuOVQhdk1? NWP6Sm1CW0GQR1XS
HCC1187 M4ewXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnqwTWM2OD1|LkW0JI5O MXTTRW5ITVJ?
MZ1-PC MmjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDG[YJXUUN3ME2zMlU1KG6P NYm1Z29KW0GQR1XS
no-11 NFe3N|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfXd|NKSzVyPUOuOVUhdk1? NInXS4pUSU6JRWK=
EVSA-T NVrxT5E1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULDW3VDUUN3ME2zMlYhdk1? MnG4V2FPT0WU
DJM-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTNwNkOgcm0> NFnsZlFUSU6JRWK=
COLO-684 MnnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHryTZFKSzVyPUOuOlYhdk1? M1vNW3NCVkeHUh?=
NMC-G1 MljUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTpTWM2OD1|Lk[4JI5O NIr5RWZUSU6JRWK=
LC-1F NV;weHE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3XfI5UUUN3ME2zMlc1KG6P MonwV2FPT0WU
RL95-2 NWTZZ3k4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInncm1KSzVyPUOuO|khdk1? M3vD[HNCVkeHUh?=
COLO-320-HSR NIHCbI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1uyfmlEPTB;Mz65NkBvVQ>? MmjKV2FPT0WU
RCC10RGB MoHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlThTWM2OD1|LkmzJI5O MX7TRW5ITVJ?
HD-MY-Z NXnINVBlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmS3TWM2OD1|LkmzJI5O NES3UWxUSU6JRWK=
NCI-H2141 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHT2SmJKSzVyPUSuNFUhdk1? M2PuXXNCVkeHUh?=
K-562 M1n3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4ixSGlEPTB;ND6xNkBvVQ>? MWLTRW5ITVJ?
NCI-H1648 NH\HUmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTRwMUOgcm0> NWXvenc3W0GQR1XS
OMC-1 M{PMO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLwW|V{UUN3ME20MlE5KG6P MlWzV2FPT0WU
LB647-SCLC NVvNOYRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPabpFYUUN3ME20MlIzKG6P MV\TRW5ITVJ?
TE-12 NYm3bnFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LmR2lEPTB;ND6yOUBvVQ>? M1nWUHNCVkeHUh?=
NOMO-1 NVuwUm86T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLPfIpKSzVyPUSuN|Mhdk1? NXT0dJJUW0GQR1XS
Raji NUTsTppET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEGwd2RKSzVyPUSuOFYhdk1? MmTDV2FPT0WU
NALM-6 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLZTWM2OD12LkS5JI5O NUWyOHk4W0GQR1XS
HL-60 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTRwNkegcm0> NGLJcJdUSU6JRWK=
IST-SL1 NVnJdVZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfNVFdKSzVyPUSuOlghdk1? MmDTV2FPT0WU
MHH-PREB-1 NWWzW4hTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHNZZBKSzVyPUSuPFYhdk1? NWLsOVQ5W0GQR1XS
MHH-NB-11 Mn23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlWwTWM2OD12LkmxJI5O MlfnV2FPT0WU
JiyoyeP-2003 NUm3TWo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInpUG9KSzVyPUWgcm0> MkLnV2FPT0WU
SBC-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXuTWM2OD13LkCxJI5O M2LENHNCVkeHUh?=
CHP-126 NIjUOWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTVwME[gcm0> NYXJbVBUW0GQR1XS
LU-139 M2Dte2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnewTWM2OD13LkGzJI5O NInscFdUSU6JRWK=
NCI-SNU-5 NWe2PGVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnXVGl4UUN3ME21MlE4KG6P M{TFcnNCVkeHUh?=
SW962 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPUTWM2OD13LkKxJI5O NHXTfWVUSU6JRWK=
EW-1 NGDKXoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzKcWxRUUN3ME21MlMyKG6P NXi3WYkxW0GQR1XS
NCI-H1417 NFzqXohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\wTWM2OD13LkWxJI5O M4f3d3NCVkeHUh?=
LU-65 MnHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTVwOESgcm0> NFHZN5FUSU6JRWK=
D-502MG NWPveGdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETFOJhKSzVyPU[uN|chdk1? M1q1fnNCVkeHUh?=
BC-3 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUG3ZVlKUUN3ME22MlYyKG6P MXzTRW5ITVJ?
GDM-1 M4T2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vVN2lEPTB;Nj63O{BvVQ>? NHXTTXhUSU6JRWK=
NCI-H2196 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjKS2pKSzVyPU[uPEBvVQ>? MoC4V2FPT0WU
NB1 NVjJcXhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TCXmlEPTB;Nj64PEBvVQ>? NF\iZXJUSU6JRWK=
NCI-H345 M33ZVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHoOWtuUUN3ME23MlIhdk1? NGjtT2JUSU6JRWK=
SU-DHL-1 NHjrXJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3frSGlEPTB;Nz6yOEBvVQ>? MU\TRW5ITVJ?
JVM-2 NEXab3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nRZmlEPTB;Nz6yPEBvVQ>? M1KwW3NCVkeHUh?=
LU-134-A MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULwepNJUUN3ME23MlM6KG6P MoLkV2FPT0WU
NCI-H1694 NFiyV5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTdwNUigcm0> NXrGe4JZW0GQR1XS
NCI-SNU-16 M2PobGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonwTWM2OD15Lk[1JI5O MVXTRW5ITVJ?
L-363 M3WzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnL4TWM2OD15Lkegcm0> NHvTVJJUSU6JRWK=
KG-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3j2OGlEPTB;Nz65OEBvVQ>? M{fYd3NCVkeHUh?=
MN-60 NFPKOFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHvTWM2OD16LkG0JI5O MkW5V2FPT0WU
NB6 NGT1bGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3idWpGUUN3ME24MlQ5KG6P M3PRWXNCVkeHUh?=
MLMA Ml71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;NemkxUUN3ME24Mlg2KG6P NX;vU4d{W0GQR1XS
ATN-1 NWT1c3ZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fLS2lEPTB;OD64PUBvVQ>? NX3LPYdVW0GQR1XS
SK-NEP-1 NUTEO|NvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3O2PWlEPTB;OT6wNUBvVQ>? NYLPSXc3W0GQR1XS
DMS-114 MnjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjSTWM2OD17Lk[yJI5O M4HhXHNCVkeHUh?=
CTB-1 M374Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPZOnVKSzVyPUmuOlchdk1? M1LBUHNCVkeHUh?=
NCI-H2081 Mo[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HlNGlEPTB;MUCuNFkhdk1? M1zpcnNCVkeHUh?=
ES5 M2f5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTFyLkO4JI5O M1HnR3NCVkeHUh?=
HCC1599 M3uyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTFzLkmxJI5O MojpV2FPT0WU
NCI-H23 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHtWFRJUUN3ME2xNk4yOiCwTR?= MYPTRW5ITVJ?
NCI-H1581 MmrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTF{LkK4JI5O MkOwV2FPT0WU
JVM-3 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTF{Lkm5JI5O NX64S4o1W0GQR1XS
NCI-SNU-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3f5S2lEPTB;MUOuNVkhdk1? NHjsS3pUSU6JRWK=
NB7 M3X4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fv[WlEPTB;MUWuPVIhdk1? NVvmRVRNW0GQR1XS
JAR M{PDZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPxTWM2OD1zNj6xN{BvVQ>? NEj0fIdUSU6JRWK=
TGW MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGmzVoZKSzVyPUG2MlQ5KG6P NXrtT2Y1W0GQR1XS
U-87-MG M{TMO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDyNWZKSzVyPUG2Mlc3KG6P M4\RdXNCVkeHUh?=
NCI-H1436 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTF5LkCxJI5O MXLTRW5ITVJ?
GOTO NV[2UGFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;4VVBKSzVyPUG3MlA3KG6P NGCxS3JUSU6JRWK=
COLO-800 NX\jdY83T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfvTlU{UUN3ME2xO{43PCCwTR?= MmXRV2FPT0WU
MFM-223 NVjGTFNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHMcllKSzVyPUG3MlkyKG6P NXfnOWlzW0GQR1XS
EW-18 NWOyNnJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vDSGlEPTB;MUeuPVYhdk1? MXzTRW5ITVJ?
NB14 M{jmWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTPdnh7UUN3ME2xO{46QCCwTR?= Ml;UV2FPT0WU
EB2 NGnIe4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTF6LkC4JI5O MnrQV2FPT0WU
EoL-1- M{f5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjmTWM2OD1zOD6zNUBvVQ>? NEfJe|dUSU6JRWK=
NCCIT M1\BOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTF6LkO2JI5O NGi3e5dUSU6JRWK=
DG-75 M1z5e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1[3fGlEPTB;MUiuOlEhdk1? MWnTRW5ITVJ?
HCC2218 M1rDU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTF7LkWgcm0> NGC3SoZUSU6JRWK=
TE-6 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDjPHdKUUN3ME2yNE4xQCCwTR?= M4LvTnNCVkeHUh?=
SF539 NV;RUZJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfveGJKSzVyPUKwMlY4KG6P Ml3TV2FPT0WU
NCI-H446 NXHmUVU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LnSWlEPTB;MkGuNVghdk1? MkS1V2FPT0WU
IST-MES1 NHjnfXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUC2PXlUUUN3ME2yNk44PyCwTR?= NF25S2xUSU6JRWK=
NCI-H82 M4HRWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTJ|LkCyJI5O NILGPGZUSU6JRWK=
HCC2157 Mn;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXITWM2OD1{Mz6xN{BvVQ>? NHfINXJUSU6JRWK=
EW-12 NFLCNpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvPbJhoUUN3ME2yN{4yPyCwTR?= M2jafnNCVkeHUh?=
SIMA NYfxU2Q3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTvOmVKSzVyPUKzMlM5KG6P M3rPOnNCVkeHUh?=
DOHH-2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTJ|LkS1JI5O M{TVcHNCVkeHUh?=
IM-9 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvsXldKSzVyPUKzMlU1KG6P MYrTRW5ITVJ?
EC-GI-10 NXfke3pXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTJ2LkKzJI5O MVfTRW5ITVJ?
HDLM-2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTJ2LkW0JI5O NI\DWHlUSU6JRWK=
LS-1034 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHu5cIJKSzVyPUK1Mlc2KG6P MmTTV2FPT0WU
REH M{i5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzn[XV7UUN3ME2yOk41OSCwTR?= MnW0V2FPT0WU
LU-165 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfDTWM2OD1{Nj63NkBvVQ>? NVHm[lJoW0GQR1XS
NH-12 MofFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmC0TWM2OD1{Nz62O{BvVQ>? MWDTRW5ITVJ?
WSU-NHL NYfVcWhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTJ6LkO5JI5O M3zYO3NCVkeHUh?=
ECC4 NUTZRYNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\0c2VsUUN3ME2yPE44QSCwTR?= NUXDVZhHW0GQR1XS
OCI-AML2 MkfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NES3eFJKSzVyPUK5MlY6KG6P MmX3V2FPT0WU
EW-3 NEnEc2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7lZVB4UUN3ME2zNE42QSCwTR?= NXjxcnVQW0GQR1XS
NCI-H526 NUHCVXgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;DU24zUUN3ME2zNk42PCCwTR?= NHL2OZBUSU6JRWK=
NCI-H719 NXnXSHQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLvTWM2OD1|ND6zNUBvVQ>? NVS2OFdvW0GQR1XS
KARPAS-422 NY\TdHRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWW0N5Q{UUN3ME2zOU4xPCCwTR?= M33tOHNCVkeHUh?=
SK-MEL-1 M3;4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTN3LkG3JI5O NGD6OoRUSU6JRWK=
ES3 NInXU3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnGTWM2OD1|NT6xPUBvVQ>? M1v5[HNCVkeHUh?=
UACC-812 NUDoN2hkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moe4TWM2OD1|NT60OEBvVQ>? MnGwV2FPT0WU
C8166 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDwWnl5UUN3ME2zOU44KG6P M3fFd3NCVkeHUh?=
MDA-MB-134-VI MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\0NGhKSzVyPUO1Mlg4KG6P NG[wWXJUSU6JRWK=
D-283MED NYrQV3Z1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfjcGhKSzVyPUO3Mlc6KG6P NX;CcZZJW0GQR1XS
SHP-77 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4roW2lEPTB;M{iuNFMhdk1? NWTpPXg5W0GQR1XS
NCI-H2227 NWq4OHZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYL0O|ZxUUN3ME20NE41QSCwTR?= NXnzU2c3W0GQR1XS
SKM-1 MmLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nsW2lEPTB;NEKuOlMhdk1? MXPTRW5ITVJ?
L-428 NXi0cJBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3mbXFOUUN3ME20N{45PiCwTR?= Moq4V2FPT0WU
RPMI-6666 NWDQTm1lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGK5XGlKSzVyPUS1Mlg6KG6P MorrV2FPT0WU
NCI-H716 NYracnlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlf6TWM2OD12OD64NUBvVQ>? NWLpRVU4W0GQR1XS
DMS-79 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLyOIRKSzVyPUWwMlcyKG6P Ml\JV2FPT0WU
RS4-11 NVexNJY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHT0b5lKSzVyPUWwMlg5KG6P NEDIVpBUSU6JRWK=
NCI-H720 MlrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGSzNZFKSzVyPUWxMlEyKG6P MVzTRW5ITVJ?
MC-CAR MmToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDPTWM2OD13MT61NkBvVQ>? MX\TRW5ITVJ?
TALL-1 NUfmVYxzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nLRmlEPTB;NUOuPVEhdk1? NEXJWVNUSU6JRWK=
NCI-N87 NXjG[G51T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfNUnU3UUN3ME21OE4yQCCwTR?= M1;FRXNCVkeHUh?=
P30-OHK NE[3THJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nzbWlEPTB;NUSuOlEhdk1? MXnTRW5ITVJ?
LP-1 MmftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVq4WYFlUUN3ME22NU4zQCCwTR?= MYHTRW5ITVJ?
YT MnfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LS[GlEPTB;NkGuPEBvVQ>? MnHGV2FPT0WU
MRK-nu-1 NY\E[XFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTZzLkiyJI5O NUL5SlJyW0GQR1XS
BT-474 MorZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrnO4hKSzVyPU[1JI5O MnHVV2FPT0WU
NCI-H322M M1zlNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTZ4LkGxJI5O MV7TRW5ITVJ?
NCI-H128 Mlz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjMc5pKSzVyPUe0Mlc4KG6P NXSwOGR[W0GQR1XS
KMS-12-PE NHuwPZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTd4LkK0JI5O M2fRdnNCVkeHUh?=
KP-N-YS NXTvdppLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2f2c2lEPTB;N{[uO|Qhdk1? NYHVPWxrW0GQR1XS
ALL-PO NWrEWlVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjTOIp3UUN3ME23O{43PiCwTR?= MoCwV2FPT0WU
EW-13 M{\UNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXxTWM2OD15Nz63OkBvVQ>? M{TTfXNCVkeHUh?=
EW-11 MmrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTd6LkWyJI5O MVfTRW5ITVJ?
SK-N-FI MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHn4T2RKSzVyPUiwMlIhdk1? NYnLZldUW0GQR1XS
CAL-148 NVKwPZdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG[yVlVKSzVyPUixMlg1KG6P NH36cWVUSU6JRWK=
RL M4DxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTh4LkC5JI5O MmLCV2FPT0WU
AM-38 M1vyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnizTWM2OD16OD6wPEBvVQ>? Mn;VV2FPT0WU
RH-1 NGXL[XJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjyTWM2OD17OT64OUBvVQ>? NFXPTWtUSU6JRWK=
NCI-H1770 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrWboVKSzVyPUGwNk41QSCwTR?= M1jIU3NCVkeHUh?=
SIG-M5 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTFyNT6wOkBvVQ>? MYPTRW5ITVJ?
GR-ST M4PHc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPoWnNKSzVyPUGxN{4{PCCwTR?= M{nQUXNCVkeHUh?=
ST486 NYDJfppiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlr4TWM2OD1zMUSuNFYhdk1? M3q5fnNCVkeHUh?=
NCI-H1650 NEXmbIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDvTWM2OD1zMUWuNlkhdk1? Mn;YV2FPT0WU
MHH-CALL-2 MoH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHmTWM2OD1zMUWuO{BvVQ>? MmrLV2FPT0WU
BV-173 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXhXFhZUUN3ME2xNlIvPzFibl2= M3fvU3NCVkeHUh?=
MC116 NHPpW5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\JTWM2OD1zNEiuPFUhdk1? M1;DeHNCVkeHUh?=
NCI-H524 MmrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTmTWM2OD1zNUmuNUBvVQ>? NYPzSlhTW0GQR1XS
SCLC-21H M13FfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPEPVhGUUN3ME2xOVkvPDFibl2= MoPtV2FPT0WU
NCI-H1304 NUPr[4RyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mom1TWM2OD1zNkmuNlEhdk1? MlLrV2FPT0WU
NCI-H510A MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzBfHZKSzVyPUG4OU4{PyCwTR?= NUDqWmJ5W0GQR1XS
NCI-H209 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnVXmxGUUN3ME2xPVYvPTJibl2= NYCzSG5LW0GQR1XS
KM-H2 NWnafWQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXaTWM2OD1zOUeuNFUhdk1? NFrKRYRUSU6JRWK=
NCI-H1395 NXHIVYd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zzb2lEPTB;MkGwMlE{KG6P M1O2b3NCVkeHUh?=
NCI-H1155 NWTRbWdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHwTWM2OD1{M{CuN|Ihdk1? M1jRTHNCVkeHUh?=
COR-L279 NX;G[IVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXRXHhVUUN3ME2yOVIvOTdibl2= M4noUnNCVkeHUh?=
NCI-H1299 M4jL[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TlOGlEPTB;Mk[xMlcyKG6P M1vSNHNCVkeHUh?=
EW-22 NFrIbVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH[2SWdKSzVyPUK2N{44PSCwTR?= MWLTRW5ITVJ?
SK-MEL-2 M3XoN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2OyXWlEPTB;MkixMlkhdk1? MnP1V2FPT0WU
KASUMI-1 NX\qPHlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHMe2hKSzVyPUK4N{4xPSCwTR?= NIKzS|BUSU6JRWK=
NCI-H187 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTJ6Nz6wPEBvVQ>? NH\H[WlUSU6JRWK=
NCI-H2171 M1XqcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTJ6OD65NkBvVQ>? MUnTRW5ITVJ?
LNCaP-Clone-FGC NFTSeWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDXNJpVUUN3ME2yPVUvOjZibl2= MWTTRW5ITVJ?
NCI-H1522 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTNyNz6wOUBvVQ>? NYXIVG1MW0GQR1XS
SCH M37Se2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIj5SXBKSzVyPUOyNk4zOiCwTR?= MlzqV2FPT0WU
THP-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTN{Mj62JI5O M4j5THNCVkeHUh?=
SNU-C1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTN4Mj6wPUBvVQ>? M2e4THNCVkeHUh?=
CA46 NGrwPVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnj6TWM2OD1|N{OuOlMhdk1? MnfFV2FPT0WU
NCI-H1963 NYXGSZVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTN6Nj6xPUBvVQ>? M{XOVHNCVkeHUh?=
DEL NUDrfoFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfFWVJKSzVyPUO5NU4zPyCwTR?= Ml\OV2FPT0WU
TUR NWHnVpM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTN7Nj62NUBvVQ>? NWD3eGZEW0GQR1XS
NCI-H226 MmjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDiSndKSzVyPUSwN{4zOyCwTR?= MX;TRW5ITVJ?
COLO-668 NEPOO4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHVWnhSUUN3ME20NFMvPTdibl2= NFzYfJhUSU6JRWK=
CPC-N MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\hfWh{UUN3ME20NFMvPzdibl2= MWLTRW5ITVJ?
NCI-H889 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jsS2lEPTB;NE[xMlkzKG6P MnnVV2FPT0WU
J-RT3-T3-5 NG\KV2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPOPFU1UUN3ME21N|IvPTdibl2= M3u5c3NCVkeHUh?=
MSTO-211H NXnxVYZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLKbXVJUUN3ME21O|QvOjZibl2= NXTBdIZXW0GQR1XS
SCC-15 NX[4WlhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\5OHlVUUN3ME22OlcvPDdibl2= NWq0b5dsW0GQR1XS
SUP-T1 NY\OSVhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TTd2lEPTB;Nki2MlA1KG6P MXHTRW5ITVJ?
DMS-153 NInFcpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfjXFFZUUN3ME23OFYvQDNibl2= M{T4WHNCVkeHUh?=
MS-1 M3jXZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XqZ2lEPTB;N{W5MlQzKG6P MkD6V2FPT0WU
TC-YIK M2rGcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTd6MT6wNUBvVQ>? MVHTRW5ITVJ?
RPMI-8866 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWD4OJA3UUN3ME2xNFA3NjJ6IN88US=> MU\TRW5ITVJ?
KY821 MkHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfHRoxHUUN3ME2xNFM3NjB2IN88US=> MYLTRW5ITVJ?
P31-FUJ NWPhW2hzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fUfWlEPTB;MUGxNk44PSEQvF2= Ml\XV2FPT0WU
COLO-824 NX7tW4lDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTF{NkGuO|gh|ryP NV;XS4Q5W0GQR1XS
U-698-M M4O2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGX1eFVKSzVyPUKyOlIvOTVizszN MoPVV2FPT0WU
TE-441-T Mn3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrpTWM2OD1{NUKxMlch|ryP MnnOV2FPT0WU
IMR-5 MoHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\EemlEPTB;M{SwPU43OiEQvF2= NIHlVIJUSU6JRWK=
NCI-H1838 Mo\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfWUlJTUUN3ME20NVg3NjN{IN88US=> NG[3O3lUSU6JRWK=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[4]

+ 展開

Kinetic Methods:

In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
細胞試験:

[5]

+ 展開
  • 細胞株: Human multiple myeloma cells line U266
  • 濃度: ~10 μM
  • 反応時間: 2 days
  • 実験の流れ:

    The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.


    (参考用のみ)
動物試験:

[3]

+ 展開
  • 動物モデル: Human plasmacytoma xenografts RPMI 8226
  • 製剤: Saline
  • 投薬量: 1 mg/kg
  • 投与方法: i.v. twice weekly for 4 weeks, then once weekly
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 76 mg/mL (197.79 mM)
Water Insoluble
Ethanol Insoluble
体内 順序で溶剤を入れること:
2% DMSO+30% PEG 300+ddH2O
5mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 384.24
化学式

C19H25BN4O4

CAS No. 179324-69-7
保管
別名 LDP-341, MLM341

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01891968 Completed Leukemia M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. August 7, 2013 Phase 2
NCT01445405 Completed Carcinoma, Squamous|Head and Neck Cancer|Oral Cancer|Laryngeal Cancer|Pharyngeal Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 5, 2008 Phase 1
NCT02211755 Recruiting Neoplasms|Myelodysplastic Syndromes National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 30, 2014 Phase 1
NCT02654990 Recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis April 27, 2016 Phase 2
NCT00011778 Completed Squamous Cell Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 22, 2001 Phase 1
NCT02658396 Withdrawn Multiple Myeloma|Multiple Myeloma in Relapse|Refractory Multiple Myeloma Dana-Farber Cancer Institute|Genus Oncology, LLC|National Institutes of Health (NIH) June 2017 Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?

  • 回答:

    S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

Proteasome信号経路図

Proteasome Inhibitors with Unique Features

相関Proteasome製品

Tags: Bortezomib (PS-341)を買う | Bortezomib (PS-341) ic50 | Bortezomib (PS-341)供給者 | Bortezomib (PS-341)を購入する | Bortezomib (PS-341)費用 | Bortezomib (PS-341)生産者 | オーダーBortezomib (PS-341) | Bortezomib (PS-341)化学構造 | Bortezomib (PS-341)分子量 | Bortezomib (PS-341)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID